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Abstract
Background: Protein degradation is essential for cell homeostasis. Targeting of proteins for degradation is often achieved
by specific protein sequences or posttranslational modifications such as ubiquitination.
Methodology/Principal Findings: By using biochemical and genetic tools we have monitored the localization and
degradation of endogenous and chimeric proteins in live primary cells by confocal microscopy and ultra-structural analysis.
Here we identify an eight amino acid sequence from the C-terminus of the short-lived GTPase RhoB that directs the rapid
degradation of both RhoB and chimeric proteins bearing this sequence through a lysosomal pathway. Elucidation of the
RhoB degradation pathway unveils a mechanism dependent on protein isoprenylation and palmitoylation that involves
sorting of the protein into multivesicular bodies, mediated by the ESCRT machinery. Moreover, RhoB sorting is regulated by
late endosome specific lipid dynamics and is altered in human genetic lipid traffic disease.
Conclusions/Significance: Our findings characterize a short-lived cytosolic protein that is degraded through a lysosomal
pathway. In addition, we define a novel motif for protein sorting and rapid degradation, which allows controlling protein
levels by means of clinically used drugs.
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Introduction
The degradation of cellular components plays a key role in the
maintenance of cellular functions. Protein degradation serves
regulatory roles in cell cycle and signalling and provides amino
acid supply for protein synthesis. The main proteolytic systems in
the cell are the proteasome machinery and the lysosomal pathway.
Whereas the proteasome has been mainly involved in the rapid
degradation of regulatory or misfolded proteins [1], lysosomes are
the sites where several degradation pathways converge, including
endocytic and autophagic pathways [2].
GTPases of the Rho family play crucial roles in the regulation of
the actin cytoskeleton, cell survival and gene expression. Among Rho
proteins, RhoB displays unique functions in the control of endocytic
traffic, influencing the sorting of signalling kinases [3–5] and growth
factor receptors [4,6]. This has important consequences for growth
factor signalling, cell survival and proliferation, contributing to the
proposed role of RhoB in tumor suppression [7,8]. RhoB is also
unique among Rho proteins due to its short half life, which has been
estimated in 2–3 h [9,10]. RhoB is an immediate early gene which is
rapidly induced by DNA damage or growth factors [11,12]. Thus,
maintaining a high RhoB turnover is important to ensure the rapid
response of RhoB levels to various stimuli. However, the molecular
basis for RhoB instability has not been elucidated.
From a structural point of view, RhoB is highly homologous to
RhoA. However, whereas RhoA is retained in the cytosol bound
to RhoGDI under resting conditions [13], RhoB is mainly a
membrane-associated protein, even in non-stimulated cells [10],
and both plasma membrane and endosomal localizations of RhoB
have been reported [14,15]. The structural basis for these
differences resides in the hypervariable C-terminal domain of
these proteins. Whereas RhoA is geranylgeranylated and possesses
polybasic sequence, RhoB presents two palmitoylated cysteine
residues (C189 and C192) close to the isoprenylation motif [16].
Hypervariable domains of monomeric GTPases of the Rho and
Ras families display unique features including distinct distributions
of charged amino acids, phosphorylation sites and lipid moieties
[17,18], which mediate specific membrane localization and
orientation, traffic and interaction with effectors [19,20]. Howev-
er, the role of hypervariable domains of G proteins in protein
stability is poorly understood.
Here we have explored the cellular pathways involved in RhoB
degradation and the structural determinants directing this process.
Our results reveal several novel striking features of RhoB: 1) this
short-lived protein is degraded through a lysosomal pathway; 2)
both, isoprenylation and palmitoylation are required for RhoB
degradation; and 3) the last eight amino acids of RhoB, which
comprise the posttranslational modification motif, are sufficient to
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8117
direct the endo-lysosomal degradation of chimeric proteins. Taken
together, our observations delineate a novel pathway for protein
degradation.
Results
RhoB Is Degraded through a Lysosomal Pathway
Protein degradation is crucial for cell homeostasis. The main
pathways for protein degradation are the ubiquitin proteasome
system and the lysosomal pathway. To elucidate the involvement
of these pathways in RhoB turnover, we used a battery of protease
inhibitors with different specificity towards both pathways (Fig. 1a).
The highly selective proteasome inhibitor lactacystin, did not
increase RhoB, whereas Z-LLL-CHO, which is less specific [21],
moderately increased RhoB levels. ALLM, a calpain-2 inhibitor,
and leupeptin, a thiol and serine protease inhibitor clearly
increased RhoB. Interestingly, the most effective compound was
chloroquine, an inhibitor of lysosomal acidification. Ubiquitinated
protein levels, indicative of proteasome inhibition, did not
correlate with increases in RhoB. None of the inhibitors increased
the levels of RhoGDI, which was used as control (Fig. 1a).
Moreover, inhibition of lysosomal degradation stabilized RhoB.
RhoB protein levels rapidly decayed in control cells upon
inhibition of protein synthesis with cycloheximide (CHX)
(Fig. 1b). However, pre-treatment with thiol protease inhibitors,
leupeptin plus E64d, or with chloroquine stabilized RhoB,
suggesting that RhoB is rapidly degraded by lysosomal proteases.
Interestingly, RhoB stabilization was also observed after disrupting
Figure 1. RhoB is degraded through a lysosomal pathway. (a) Confluent serum-deprived bovine aortic endothelial cells (BAEC) were treated
with 10 mM lactacystin, 50 nM Z-LLL-CHO, 10 mM ALLM, 50 mg/ml leupeptin or 10 mM chloroquine for 24 h. Cell lysates (20 mg of protein) were
analyzed by Western blot. RhoB and ubiquitinated protein levels corrected by RhoGDI levels are shown as average values 6 SEM of three
experiments (*p,0.05 vs control). (b) BAEC were pre-treated with the inhibitors for 30 min. NH4Cl and bafilomycin A1 were added at 30 mM and
5 nM, final concentrations, respectively. RhoB levels were assessed before and after treatment with CHX (20 mg/ml). Levels of RhoGDI were used as
control. The percentage of RhoB remaining after 3 h CHX treatment is shown as average values 6 SEM of at least three different experiments
(*p,0.05 vs control). (c) BAEC were treated with 50 mg/ml leupeptin plus 5 mg/ml E64d or 10 mM chloroquine for 24 h and visualized by
immunofluorescence (IF) of endogenous RhoB (green) and staining with 500 nM LTR (red) and DAPI (blue). Images shown are single confocal
sections. Bar, 20 mm. (d) BAEC were treated with 30 mM NH4Cl or 5 nM bafilomycin A1 for 24 h and fixed. Nuclei were stained with DAPI (blue) and
RhoB (green) was detected by IF and confocal microscopy. Images are shown as maximal projections of confocal planes of 0.5 mm Z-sections. Bar,
20 mm. (e) BAEC subjected to osmotic shock for 5 min were allowed to recover in the absence or presence of 10 mM potassium chloride (K+) for 3 h,
during which CHX (20 mg/ml) was present to block new protein synthesis. RhoB levels were assessed by Western blot.
doi:10.1371/journal.pone.0008117.g001
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the endo-lysosomal pathway through various strategies including
reduction of lysosomal acidification by NH4Cl or inhibition of the
vacuolar H+-ATPase with bafilomycin A1 (Fig. 1b).
RhoB showed a characteristic punctuate pattern in control cells
(Fig. 1c). However, cells treated with inhibitors of lysosomal
degradation showed large accumulations of RhoB that were also
stained with the fluorescent probe for acidic vesicles Lysotracker
Red (LTR). RhoB co-localized with the lysosomal protease
cathepsin B, both in control and in chloroquine-treated cells
(Fig. S1). NH4Cl and bafilomycin A1 also induced marked RhoB
accumulation (Fig. 1d). Interestingly, osmotic shock followed by
potassium depletion, which disrupts both plasma and intracellular
membrane-associated clathrin lattices [22] completely stabilized
RhoB (Fig. 1e).
The major pathway leading to lysosomal degradation of
intracellular components, including long-lived proteins and
organelles, is macroautophagy [23]. Blocking autophagy by
deletion of the Atg5 gene, as in Atg5(2/2) MEFs or by means
of the classical inhibitor 3-methyladenine failed to increase RhoB
levels or stability (Fig. S2). Thus, RhoB stabilization by inhibitors
of lysosomal proteolysis is not the result of a general disruption of
vesicular traffic or of the autophagic pathway, but of selective
events in the endo-lysosomal pathway.
A higher resolution of RhoB-positive endosomal structures
could be achieved by confocal microscopy in live cells. Similarly to
endogenous RhoB, GFP-RhoB and RFP-RhoB localized to
intracellular vesicles and to the plasma membrane (Fig. 2a,b).
The localization of RhoB along the endocytic pathway was
confirmed by its presence on vesicles containing endocytosed
dextran (Fig. 2a). Interestingly, RhoB was not associated with
GFP-Rab5-positive structures but was clearly observed inside
vesicles delimited by Rab7, a marker of late endosomes and
lysosomes (Fig. 2b). RFP-RhoB was clearly localized inside
Lamp1-GFP positive vesicles and GFP-RhoB-positive vesicles
showed LTR staining (Fig. 2c). Thus, RhoB is associated with late-
endosomes/lysosomes. Interestingly, blocking lysosomal degrada-
tion with leupeptin plus E64d or with chloroquine induced the
accumulation of RhoB constructs in enlarged lysosomal vesicles
(Fig. 2c and S3a). Remarkably, RhoB distribution inside the
vesicles showed a patchy appearance, indicative of its presence in
intravesicular structures. Indeed, a greater magnification of these
dilated compartments, either in GFP-RhoB or Lamp1-GFP
transfected cells, revealed multiple intraluminal vesicles, typical
of multivesicular bodies (MVB) (Fig. S3b). Electron microscopy
(EM) clearly showed the formation of dilated multivesicular
structures in chloroquine-treated cells, that could correspond to
MVB or to late endosome/lysosome hybrids [24] (Fig. 2d).
Immuno-EM (IEM) confirmed the presence of GFP-RhoB in the
intraluminal vesicles of MVB both in control and in chloroquine-
treated cells (Fig. 2e). Taken together, these results suggest that
RhoB, localized in late endosomes/MVB may be delivered to the
luminal space and be degraded in this compartment and/or in
lysosomes.
Specific Lipids Regulate RhoB Accumulation into MVB
The biogenesis of MVB from late endosomes occurs through a
complex mechanism involving protein and lipid-mediated pro-
cesses. Lipid composition and dynamics are crucial for MVB
biogenesis [25]. Thus, we explored whether altering late endosome
lipids affected RhoB distribution. For this we used the compound
U18666A, which causes the accumulation of the late endosome-
specific lipid, 2,29-dioleoyl lysobisphosphatidic acid (LBPA) and
cholesterol in late endosomal membranes [26,27] and promotes
their invagination [28]. U18666A induced a massive accumulation
of membranes and/or vesicles inside late endosomes giving rise to
electron-dense structures (Fig. 3a), that were also visible by
differential interference contrast imaging (DIC) (Fig. 3b). Remark-
ably, U18666A-induced dense MVB showed an intense accumu-
lation of GFP-RhoB (Fig. 3b). RhoB co-localized with LTR and
LBPA inside U18666A-induced structures (Fig. 3c a–d). In
contrast, Rab7, which is bi-geranylgeranylated, was retained at
the limiting membranes (Fig. 3c e,f ). Thus, disruption of late
endosome lipid dynamics promotes a selective trapping of RhoB in
these structures. The presence of GFP-RhoB in the intraluminal
membranes of U18666A-induced dense MVB was confirmed by
IEM (Fig. 3e). U18666A did not increase RhoB levels or protein
stability (Fig. S4), suggesting that RhoB degradation is not
impaired in U18666A-treated cells.
LBPA plays a key role in membrane invagination leading to
MVB formation by promoting luminal vesicle formation due to its
cone-shaped structure [29] and controls late endosome cholesterol
dynamics [26]. The role of LBPA in MVB invagination can be
specifically tackled in vivo by treatment with an anti-LBPA
antibody, which is endocytosed and accumulates in late endo-
somes blocking LBPA-dependent dynamics [26]. Anti-LBPA
induced a marked distortion of GFP-RhoB-positive endosomes
that appeared as dilated structures containing anti-LBPA (Fig. 3f),
confirming that late endosome-specific lipids regulate RhoB
sorting into MVB.
Genetic alterations of the endo-lysosomal pathway cause
various severe human diseases. The dynamics of late endo-
some-specific lipids is profoundly altered in Niemann-Pick type C
disease [26], a neurodegenerative disorder in which a mutation in
the NPC1 protein, a regulator of vesicular cholesterol transport
[30], causes massive accumulation of cholesterol and LBPA in
late endosomes. Using fibroblasts from NPC1 patients, we
observed an increase in both, the size of RhoB and LTR positive
vesicles and of RhoB-LTR co-localization with respect to
fibroblasts from control subjects (Fig. 3g). NPC fibroblasts also
showed a marked increase in endosomal cholesterol content, as
revealed by filipin staining, which co-localized with RhoB (Fig.
S5). These findings show that RhoB distribution is altered in a
relevant pathological condition affecting late-endosome lipid
dynamics.
RhoB Sorting into MVB Requires Integrity of the ESCRT
Machinery
MVB formation involves assembly of the multiprotein
complexes known as ESCRT on the late endosomal membrane.
Subsequently, recruitment of the ATPase Vps4 and ATP
hydrolysis drives the dissociation of the ESCRT machinery,
and allows the intraluminal release of vesicles formed by
endosomal membrane invagination [31]. Vps4 transiently
associates with late endosomes and is mainly cytosolic. In
contrast, ATPase-defective Vps4 mutants fail to dissociate from
these membranes and severely impair MVB sorting [32]. We
observed that whereas GFP-Vps4 wt did not alter RhoB
distribution in control or in chloroquine-treated cells (Fig. 4a),
the ATPase-defective mutant GFP-Vps4 E223Q, which acts as a
dominant negative (DN) [32], drastically reduced the formation
of RhoB-containing dilated MVB elicited by chloroquine.
Instead, RhoB appeared in small vesicles or retained at the edge
of large vesicles (Fig. 4a). Vps4 DN also impaired the formation of
chloroquine-elicited enlarged LTR-positive vesicles (Fig. 4b). We
next explored the role of Vps4 in RhoB degradation (Fig. 4c,d).
First, BAEC were transfected with the constructs of interest and
incubated with CHX under conditions resulting in the degrada-
tion of most of endogenous RhoB protein. Due to low
Lysosomal Degradation Sequence
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transfection efficiency, the presence of RhoB was assessed in
transfected and non-transfected (NT) cells by IF. After CHX
treatment, the proportion of RhoB positive cells was clearly
reduced in the cases non-transfected (NT) cells and cells
transfected with Vps4 wt but was preserved in cells transfected
with Vps4 DN (Fig. 4c). Levels of RhoGDI did not decrease after
Figure 2. Localization of RhoB along the endo-lysosomal pathway. (a) BAEC transiently transfected with GFP-RhoB were incubated with
Texas Red-labeled dextran (Dextran-TXR) for 5 min and visualized by confocal microscopy after 1 h. Bar, 20 mm. (b) BAEC were transiently transfected
with the indicated constructs and 24 h later live cells were observed by confocal microscopy. Bars, 15 mm. (c) BAEC were transfected with GFP-RhoB,
RFP-RhoB and/or Lamp1-GFP and treated 24 h later with leupeptin plus E64d or chloroquine for further 24 h. When indicated, cells were incubated
with 25 nM LTR for 15 min. Live cells were observed by confocal microscopy. Bars, 15 mm. (d) Transmission EM of MVB from control and chloroquine
treated BAEC. Bars, 1 mm. (e) IEM analysis of GFP-RhoB in control and choroquine-treated cells by staining with anti-GFP antibody. Bars, 1 mm.
doi:10.1371/journal.pone.0008117.g002
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Figure 3. Effect of endosomal lipid dynamics on RhoB distribution. (a) BAEC were treated with vehicle or 10 mM U18666A for 24 h, fixed and
analyzed by transmission EM. Bars, 1 mm. (b) Confocal microscopy GFP-RhoB-transfected cells treated as in A. DIC, fluorescent image and their overlay
are shown. Bars, 20 mm. (c) BAEC were transfected with the indicated constructs and treated with vehicle or U18666A; (a,b) and (e,f), confocal
microscopy of live cells incubated with 25 nM LTR; cell contours are shown by dotted lines in (e,f); (c,d) distribution of LBPA observed by IF. Nuclei
were stained with DAPI. Bars, 10 mm. (d) The degree of internalization of GFP-RhoB or GFP-Rab7 into U18666A-induced structures was estimated from
co-localization of the corresponding constructs with LTR and it is shown as average values 6 SEM from three independent experiments (*p,0.05 vs
control). (e) BAEC transfected with GFP-RhoB and treated with U18666A were analyzed by IEM with anti-GFP antibodies. Bar, 0.5 mm. (f) Effect of anti-
LBPA on RhoB distribution. BAEC transfected with GFP-RhoB were incubated with a control antibody or with anti-LBPA (hybridoma supernatant
diluted 1:1 in culture medium) for 20 h; (a,b) live cells observed by confocal microscopy; (c,d) accumulation of LBPA observed by IF with anti-mouse Ig
antibody. Bars, 20 mm. (g) Control or NPC fibroblasts were transfected with GFP-RhoB. Co-localization with LTR was assessed in live cells. Bars, 20 mm.
Co-localization is shown as average values 6 SEM of determinations from three experiments (*p,0.05 vs control).
doi:10.1371/journal.pone.0008117.g003
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Figure 4. Effect of Vps4 wt and DN on RhoB localization and stability. (a–b) BAEC were transfected with GFP-Vps4 wt or DN, as indicated,
and 24 h later, treated in the absence or presence of 10 mM chloroquine for 24 h. In (b), 25 nM LTR was added 15 min before observation of live cells
by confocal microscopy. Bars, 15 mm. (c) BAEC were transfected as above and 24 later placed in serum-free medium. After 24 h, control (0 time, -) cells
were fixed, and the rest were treated with 20 mg/ml CHX for 8 h (+) to allow degradation of endogenous RhoB, before fixation. Endogenous RhoB (in
red) was detected by IF. Nuclei were stained with DAPI. Images shown are overall projections. Bars, 20 mm. The lower panel shows the proportion of
RhoB-positive cells among non-transfected (NT) cells or among cells transfected with the indicated constructs before (2) or after CHX (+) treatment.
At least 40 cells of each type were monitored from four independent experiments. Results are shown as average values6 SEM (*p,0.05 vs the same
condition in the absence of CHX). (d) COS7 cells were transfected with GFP-Vps4 wt or DN, as indicated, and 24 h later split in three dishes for
treatment with CHX for the indicated times. RhoB and RhoGDI levels were assessed by Western blot. Results shown are average values 6 SEM from
three experiments (*p,0.05 vs GFP-Vps4 DN at the same time points).
doi:10.1371/journal.pone.0008117.g004
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CHX treatment (Fig. S6). The effect of Vps4 on RhoB levels was
determined in COS7 cells, which allow high transfection
efficiency. As it is shown in Fig. 4d, the decay in RhoB levels
upon CHX treatment was slower in Vps4 DN-transfected than in
Vps4 wt-transfected cells. Taken together these results indicate
that blocking Vps4 function prevents both RhoB sorting into
MVB and degradation.
The C-Terminal Sequence of RhoB (-CINCCKVL) Acts as a
Signal for Protein Endo-Lysosomal Localization and
Degradation
Lipid modifications of G proteins are key for their specific
subcellular localization. To assess the relative importance of the
individual lipidic modifications in RhoB localization and stability
we generated site-specific mutants. As we reported previously [10],
an isoprenylation-deficient mutant, RhoB C193S, failed to
associate with cellular membranes and its turnover was completely
inhibited (Fig. 5a). Mutation of the first palmitoylation site
(C189S), induced a diffuse cytosolic distribution with a perinuclear
accumulation and partially impaired degradation, whereas
mutation of the second palmitoylation site (C192S) completely
stabilized RhoB, same as the double C189,192S mutation. All
palmitoylation mutants excluded the nucleus, indicating that
isoprenylation is preserved. Thus, both palmitoylation sites
contribute to the localization and degradation of RhoB, although
to different extents. We next seek to modulate RhoB turnover
pharmacologically by interfering with isoprenylation and palmi-
toylation. Both simvastatin, an isoprenoid biosynthesis inhibitor,
and 2-bromopalmitate, a palmitoylation inhibitor, increased the
levels of GFP-RhoB and endogenous RhoB, but not of RhoA (Fig.
S7). Moreover, short-term treatment (3 h) with either inhibitor
elicited the appearance of diffusely distributed GFP-RhoB, which
excluded the nucleus in the case of 2-BP, but not in the case
of simvastatin-treated cells (Fig. S7c). Since isoprenylation is
irreversible, the effect of simvastatin is consistent with the diffuse
localization of the newly synthesized non-processed protein. Thus,
isoprenylation and palmitoylation may act as switches for RhoB
degradation.
RhoA is 86% identical to RhoB differing mainly in the C-
terminal sequence. As shown in Fig. 5a, GFP-RhoA was cytosolic
and stable, suggesting that RhoB C-terminus contains the
structural determinants for degradation. To test this hypothesis,
we prepared chimeric proteins of GFP with several short
sequences from RhoB C-terminus (Fig. 5b). Interestingly,
chimeric proteins containing only the last 22, or even the last 8
amino acids of RhoB, showed a GFP-RhoB-like distribution,
and were not stable. In contrast, the fusion protein containing
only the CAAX box appeared diffuse with a perinuclear
accumulation, and was not detectably degraded. Thus, the
isoprenylation motif alone is not sufficient, but a sequence
containing the isoprenylation and the two palmitoylation sites of
RhoB (CINCCKVL) efficiently directs protein localization and
degradation.
In order to investigate if this sequence was targeting chimeric
proteins for degradation through a lysosomal pathway, we assessed
the localization of the GFP-CINCCKVL construct, termed GFP-
8, in the presence of lysosomal inhibitors. GFP-8 significantly co-
localized with RFP-RhoB and LTR in control cells (Fig. 6a).
Moreover, in cells treated with chloroquine or with bafilomycin A1
GFP-8 was retained inside LTR-positive dilated vesicles, likewise
GFP-RhoB/LTR (Fig. 2c). Furthermore, GFP-8 accumulated in
U18666A-induced dense MVB visible by DIC (Fig. 6b), where it
co-localized with RFP-RhoB and LBPA (Fig. 6c). Thus, GFP-8 is
internalized into MVB by mechanisms similar to those operating
on RhoB.
Targeting Stable Proteins for Rapid Lysosomal
Degradation through the CINCCKVL Sequence
To assess the ability of the CINCCKVL sequence to induce
endo-lysosomal localization and rapid degradation of stable
cytosolic proteins we created additional chimeras. TagRFP, a
monomeric protein only 29% identical to GFP, was diffuse and
did not co-localize with GFP-RhoB or Lamp1-GFP (Fig. 7a). In
contrast, the chimeric protein tagRFP-CINCCKVL (tagRFP-8)
co-localized with GFP-RhoB-positive vesicles and appeared inside
Lamp1-GFP-delimited vesicles. In chloroquine-treated cells,
tagRFP remained excluded from RhoB-containing and Lamp1-
delimited dilated MVB, whereas tagRFP-8 was totally accumu-
lated inside. Moreover, whereas tagRFP was stable, tagRFP-8
reached lower levels and was rapidly degraded (estimated half-life
of tagRFP-8 #3 h; Fig. 7b). As expected, tagRFP-8 migrated
faster than tagRFP in SDS-PAGE gels, a feature typical of other
isoprenylated and palmitoylated proteins, like RhoB or H-Ras
[10,33].
As shown above, the levels of the cytosolic protein RhoGDI are
not altered by agents modulating lysosomal protein degradation or
endosomal traffic and they remain stable after inhibition of protein
synthesis (Fig. 1). Therefore, we considered it a good candidate to
confirm the effect of the addition of the CINCCKVL sequence to
its C-terminal end. Whereas GFP-RhoGDI was diffuse, GFP-
RhoGDI-CINCCKVL (GFP-RhoGDI-8) was associated with
LTR-positive cytosolic vesicles and strongly co-localized with
RFP-RhoB (Fig. 7c). Moreover, in chloroquine-treated cells, GFP-
RhoGDI was excluded from, whereas GFP-RhoGDI-8 was
accumulated in LTR and RhoB-positive dilated vesicles (Fig.
S8), thus corroborating the lysosomal localization of the chimeric
protein. GFP-RhoGDI-8 lysosomal targeting was sensitive to
modulation of isoprenylation. Treatment of cells expressing
membrane and vesicle-associated GFP-RhoGDI-8 with simvasta-
tin led to its diffuse localization throughout the cytosol (Fig. 7d, a
and b). Conversely, when cells were transfected with GFP-
RhoGDI-8 in the presence of simvastatin, the protein was
completely cytosolic (Fig. 7d c) but removal of the statin allowed
its appearance in cytosolic vesicles (Fig. 7d d).
As observed with other -CINCCKVL chimeric proteins, the
levels and the half-life of GFP-RhoGDI-8 were consistently lower
than those of GFP-RhoGDI and endogenous RhoGDI (Fig. 7e).
Interestingly, simvastatin increased the levels of GFP-RhoGDI-8
but not of GFP-RhoGDI (Fig. 7f). These results indicate that C-
terminal processing can act as a switch for the localization and
degradation not only of RhoB but of chimeric proteins bearing
the CINCCKVL motif. The specific subcellular localization and
reduced protein stability of GFP-RhoGDI-8 (half-life #3 h) were
also observed in stably transfected NIH-3T3 fibroblasts (Fig. S8),
ruling out a potential interference of lipid-mediated transfection
in the effects observed. Finally, we confirmed that the
CINCCKVL motif rendered GFP-RhoGDI-8 susceptible to
modulation by lysosomal proteolysis inhibitors. Leupeptin and
chloroquine increased GFP-RhoGDI-8 levels, whereas GFP-
RhoGDI and endogenous RhoGDI remained unchanged (Fig. 7f).
Taken together, these results show that the CINCCKVL
sequence is capable of promoting a RhoB-like localization and
degradation rate when fused to the C-terminal end of unrelated
proteins like GFP, tagRFP and GFP-RhoGDI. Moreover, both
the levels and distribution of the chimeric proteins can be
regulated pharmacologically by means of widely used drugs, such
as statins.
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Figure 5. Structural determinants involved in the subcellular localization and degradation of GFP-RhoB. (a,b) NIH-3T3 fibroblasts were
transiently transfected with the indicated GFP constructs. 24 h after transfection, the distribution of fluorescent constructs was assessed by confocal
microscopy of live cells. Bars, 20 mm. The putative posttranslational modifications of each construct are shown schematically above the panels.
Construct stability was assessed by blocking protein synthesis with CHX and estimating the remaining levels by Western blot with anti-GFP antibody.
Blots show the levels of the constructs of interest and of RhoGDI, as control. Lower panels show the construct levels remaining after 6 h treatment
with CHX. wt, GFP-RhoB; C193S, GFP-RhoB C193S; C189S, GFP-RhoB C189S; C192S, GFP-RhoB C192S; C189,192S, GFP-RhoB C189,192S; RhoA, GFP-
RhoA. Results are shown as average values 6 SEM of three different experiments (*p,0.05 vs wt levels in (a) and vs GFP-4 levels in (b)).
doi:10.1371/journal.pone.0008117.g005
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Discussion
Rapid protein degradation contributes to the tight control of
RhoB levels. The study of the mechanisms responsible for RhoB
degradation points to the existence of a degradation pathway
(schematized in Fig. S9) by which RhoB, a cytosolic protein, is
delivered into MVB and is degraded in acidic compartments. This
process depends on the function of proteins of the Vps machinery
and on RhoB posttranslational modification, which mediates its
association with late endosomes. Moreover, a sequence of only
eight amino acids comprising the RhoB lipidation motif can ‘‘pull’’
other proteins towards an endo-lysosomal compartment for rapid
degradation.
The finding that the lysosomal pathway achieves the rapid
degradation of RhoB is relevant because the proteasome is
considered responsible for the degradation of most short-lived
proteins [1]. Autophagy constitutes the major pathway leading to
lysosomal degradation [23]. Our results indicate that macro-
autophagy is not responsible for RhoB degradation. This is
consistent with observations indicating that autophagy does not
play an obvious part in the degradation of short-lived proteins,
even under serum deprivation conditions [34]. On the other hand,
the CINCCKVL sequence does not respond to the any of the
consensus sequences that elicit chaperone-mediated autophagy
[35]. In contrast, our results imply that RhoB reaches lysosomes
through the endocytic pathway. RhoB is found in MVB and is
strongly accumulated in this compartment when the MVB lipids
are selectively altered either by pharmacological means, such as
U18666A and endocytosed anti-LPBA antibodies, or by genetic
disease. Although these conditions clearly affect MVB membrane
dynamics, it is not clear how they would affect lysosomal
degradation. Endocytosed anti-LBPA antibodies do not impair
EGFR degradation [36], whereas U18666A reduces late endo-
some acidification. Thus the lack of a detectable effect of this
compound on RhoB degradation could be the net result of
increased invagination and compromised proteolytic activity [37].
It is interesting to note that lipid-mediated ‘‘trapping’’ of RhoB
into MVB is selective since Rab7, which is also associated with the
late endosome limiting membrane, is not accumulated in this
compartment. This could arise from the strong binding of RhoB to
defined endosomal membrane domains resulting in its remaining
associated with invaginating membranes. In fact, RhoB extraction
from membranes requires high detergent concentrations (unpub-
lished observations).
Given the clear role of MVB membrane invagination in RhoB
sorting we used a powerful strategy to block this process. DN Vps4
brings about an overall impairment of the ESCRT machinery and
blocks intraluminal vesicle formation [38]. The inhibition of RhoB
degradation specifically observed in Vps4 DN-transfected cells
confirms that RhoB is degraded through an endo-lysosomal
pathway requiring MVB biogenesis.
The observation that palmitoylation appears to play a positive
role in RhoB degradation constitutes a singular case since, in
mammalian cells, palmitoylation most often targets proteins away
Figure 6. Localization of GFP-CINCCKVL in endo-lysosomal compartments. (a) BAEC transfected with RFP-RhoB and/or GFP-CINCCKVL
(GFP-8) were treated with vehicle, 10 mM chloroquine or 5 nM bafilomycin A1, incubated with 25 nM LTR when indicated and visualized live by
confocal microscopy. (b) BAEC transfected with GFP-8 were treated with 10 mM U18666A for 24 h. DIC and fluorescence images showing dense
lysosomes and GFP-8 accumulations are shown. (c) BAEC transfected with GFP-8 and RFP-RhoB and treated with U18666A as above were fixed and
co-localization of GFP-8, RFP-RhoB and LBPA was detected by IF. Bars, 20 mm.
doi:10.1371/journal.pone.0008117.g006
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Figure 7. Subcellular localization and stability of chimeric proteins bearing -CINCCKVL C-terminal sequences. (a) BAEC were co-
transfected with tagRFP or tagRFP-CINCCKVL (tagRFP-8) and GFP-RhoB or Lamp1-GFP, as indicated, treated for 24 h in the absence or presence of
10 mM chloroquine and directly visualized by confocal microscopy. Images shown are individual confocal sections. Bars, 20 mm. (b) The stability of
tagRFP and tagRFP-8 was assessed in BAEC as described in Fig. 5, using an anti-tagRFP antibody. Results are shown as average values6 SD of at least
three determinations (*p,0.05 vs tagRFP levels at the same time points). (c) BAEC were transfected with GFP-RhoGDI, GFP-RhoGDI-8 and/or RFP-
RhoB, incubated with 25 nM LTR, as indicated, and directly observed by confocal microscopy. Bar, 20 mm. (d) BAEC were transfected with GFP-
RhoGDI-8 in the absence (a) or presence (c) of 10 mM simvastatin. 24 h after transfection, confocal images of live cells were obtained (a, c). At that
point, simvastatin was withdrawn from (c) and added to (a). After a 24 h additional incubation images of live cells were taken (b, d). Bar, 20 mm. (e,f)
BAEC were transiently transfected with GFP-RhoGDI-8 or GFP-RhoGDI. In (e) protein synthesis was blocked by CHX addition. In (f) BAEC were treated
with the indicated agents for 24 h. Levels of GFP-RhoGDI-8, GFP-RhoGDI and endogenous RhoGDI, were assessed by Western blot. Sv, simvastatin;
Chlo, chloroquine; Leu, leupeptin.
doi:10.1371/journal.pone.0008117.g007
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from lysosomes, resulting in increased stability [39–42]. The
CINCCKVL sequence is unique to RhoB as determined by
BLAST and is conserved in all species in which the RhoB
sequence is available. However, several proteins belonging to the
Ras superfamily, including H-Ras, TC10 and Rap2 possess
palmitoylated cysteines close to the isoprenylated C-terminus.
Nevertheless, these proteins contain specific features in their
hypervariable domains including distinct distributions of acidic
and basic amino acids and/or spacing of lipidated residues that
result in a different subcellular localization in spite of possessing a
lipidation motif similar to that of RhoB [20]. More distantly, in
yeast, palmitoylation of Vac8 and Ykt6, the latter being also
isoprenylated, has been found to direct localization at the vacuole
[43,44], although at present, there is no information on its role on
protein stability. Future studies will address whether similar
mechanisms may operate for other proteins.
Our results show that the sequence containing RhoB isopreny-
lation and palmitoylation sites (CINCCKVL) is sufficient to
promote a RhoB-like localization and degradation rate when fused
to the C-terminal end of several unrelated proteins. Therefore, an
interesting aspect of our studies is the potential use of the
CINCCKVL sequence to control the localization and cellular
levels of proteins of interest. For instance, chimeric proteins
bearing this sequence could be potentially used for delivering
bioactive components to the endo-lysosomal compartment to
modulate lysosomal function, which has broad implications for cell
viability, both in carcinogenesis and degenerative processes.
Moreover, levels of CICNCKVL-ending proteins can be increased
by lysosomal protease inhibitors. This raises the possibility of using
these chimeric proteins as reporters of lysosomal proteolytic
activity. Importantly, isoprenylation and palmitoylation can act as
switches for the lysosomal targeting and degradation of chimeric
proteins bearing CINCCKVL C-terminal sequences. Thus, levels
of CINCCKVL-ending chimeric proteins can be regulated by
commonly used drugs such as simvastatin. Also, given the
increasing interest for the clinical use of isoprenylation inhibitors,
the potential for use of CINCCKVL contructs for monitoring
isoprenylation efficiency in living cells can be hypothesized.
Finally, identification of this novel protein degradation sequence
may provide valuable tools to study the mechanisms of MVB
formation and lysosomal proteolysis in health and disease.
Materials and Methods
Cell Culture and Treatments
BAEC were obtained and cultured as previously described [10].
NIH-3T3 fibroblasts or COS7 cells, cultured as described [10]
were treated with the indicated agents or vehicle in the absence of
serum. Human primary fibroblasts from apparently healthy
subjects and Niemann-Pick disease patients were from Coriell
Institute for Medical Research (Candem, NJ). MEFs from wt and
Atg5(2/2) mice were kindly provided by Dr. N. Mizushima.
Antibodies and Reagents
Antibodies for Western blot were anti-RhoB (sc-180), anti-
RhoGDI (sc-360), anti-RhoA (sc-418), and anti-ubiquitin (sc-
8017), from Santa Cruz Biotechnology (Heildelberg, Germany),
anti-GFP from Clontech (Palo Alto, CA) and anti-tagRFP from
Evrogen (Moscow, Russia). Antibodies for IF were anti-RhoB (sc-
8048) and anti-RhoGDI (sc-360), from Santa Cruz Biotechnology,
and anti-cathepsin B from Calbiochem. Anti-LBPA was from
Echelon Biosciences Inc. (Salt Lake City, UT). Bafilomycin A1 was
from A.G. Scientific, Inc. (San Diego, CA). LTR was from
Molecular Probes (Invitrogen). Simvastatin was a gift form Merck,
Sharp & Dohme (Madrid, Spain).
Plasmids and Transfections
pEGFP-C1 and pDsRed1-C1 were from Clontech. pTagRFP-C
was from Evrogen. Human RhoGDI cDNA was from Origene
(Rockville, MD). The pcDNA3-HA-RhoB plasmid was generously
provided by Dr. G.C. Prendergast. Lamp1-GFP was from Prof.
Jennifer Lippincott-Schwartz (NIH, Bethesda, MD). GFP-Rab7 wt
was kindly provided by Prof. Cecilia Bucci (University of Copenha-
gen, Denmark). GFP-Vps4 wt and E334Q were the generous gift of
Dr. Philip Woodman (University of Manchester, UK).
The generation of pEGFP-C1-HA-RhoB wt and C193S mutant
has been described [10]. Palmitoylation-deficient mutants of RhoB
were generated by PCR using oligonucleotides: 59-GCTCTA-
GATCATAGCACCTTGCACGAGTTGATGC-39, 59-GCTC-
TAGATCATAGCACCTTGCAGCAGTTGATCGAGCCATT-
CTG-39, and 59-GCTCTAGATCATAGCACCTTGCACGAG-
TTGATCGAGCCATTCTG-39 for the C192S, C189S, and
C189,192S mutants, respectively. Mutation sites are underlined.
Constructs encoding chimeric proteins comprising GFP and
various sequences from the RhoB or TC-10 C-terminus, were
generated by PCR using pEGFP-C1 as a template. The forward
primer was common for all constructs: 59-GAGTAGAAGCT-
TATGGTGAGCAAGGGCGAGGAG-39. Reverse primers were
59-CCGAATTCTAGAGGACCTTGCACTTGTACAGCTCGT-
CC-39, 59-CCGAATTCTAGAGGACCTTGCAACAGTTGAT-
ACACTTGTACAGCTCGTCCATGC-39 and 59-CCGAATT-
CTCACGTAATTAAACAACAGTTGATACACTTGTA CAG-
CTCGTCCATGC-39 for generating the GFP-CKVL, GFP-CI-
NCCKVL (GFP-8) and GFP-CINCCLIT (GFP-8T) constructs,
respectively. PCR products were digested with HindIII and EcoRI
and cloned into pcDNA3.0. The construct encoding GFP plus the
last 22 amino acids of RhoB was generated by amplifying GFP
with a BssHII site at its 39 end, using pEGFP-C1 as a template and
primers, forward 59-GAGTAGAAGCTTATGGTGAGCAAGG-
GCGAGGAG-39, and reverse 59-CATCTTGCGCGCGTCT-
TGTACAGCTCGTCC-39. The PCR product was subcloned
into the HindIII-BssHII sites of pcDNA-RhoB. The BssHII site is
located at position 806 of the sequence of the rat RhoB gene
(NM_022542). Therefore, this construct contains the C-terminal
sequence of RhoB from T175. pRFP-RhoB was generated by
cloning HA-RhoB into the BglII-EcoRI sites of pRFP. For
generation of the construct encoding tagRFP-CINCCKVL,
tagRFP was amplified by PCR using pTagRFP-C as template
and oligonucleotides, forward 59- CCGCTAGCGCTACCGG-
TCGCCACCATGG-39 and reverse, 59- CCGGATCCCTA-
GAGGACCTTGCAACAGTTGATACAATTAA GTTTGTGC-
CCCAGTTTGC-39. The PCR product was subcloned into the
NheI-BamHI sites of the pTagRFP-C plasmid. The cDNA of
human RhoGDI (Origene Technologies, Inc. Rockville, MD) was
amplified with oligonucleotides introducing restriction sites for
SacI or Eco RI: forward primer 59- CCGAGCTCAAATGGCT-
GAGCAGGAGCCC-39, reverse primer 59- CCGAATTCT-
CAGTCCTTCCAGTCCTTCTTGATGG-39. The PCR prod-
uct was cloned into the SacI-EcoRI sites of the pEGFP-C1
plasmid. For generation of GFP-RhoGDI-CINCCKVL, the
same strategy was used except that the oligonucleotide 59-
CCGAATTCCTAGAGGACCTTGCAACAGTTGATACAG-
TCCTTCCAGTCCTTCTTGATGG-39 was used as reverse
primer.
Confluent BAEC or NIH-3T3 fibroblasts or COS7 cells at 80%
confluence were transfected with Lipofectamine 2000 (Invitrogen)
using 1 mg of construct following the manufacturer instructions.
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Western Blots
SDS-PAGE and Western blot analysis were performed as
described [10] using ECL detection (Amersham, Buckingham-
shire, UK). Levels of the proteins of interest were estimated by
image scanning of non-saturated ECL exposures and corrected by
the band intensities of the Coomassie staining of membranes or by
the signal given by an antibody against a non-related protein
(RhoGDI for most experiments).
Fluorescence Microscopy
Cells were cultured on glass bottom dishes (Mattek Corp.,
Ashland, MA), transfected with fluorescent constructs, treated with
the indicated agents and visualized directly on a confocal
microscope (LEICA DMRE2, Heidelberg, Germany). For IF cells
were fixed with 4% paraformaldehyde, permeabilized with 0.1%
SDS, and incubated with primary antibodies and secondary
Alexa-Fluor conjugated antibodies (Invitrogen), counterstained
with DAPI (Invitrogen) and mounted with Fluoromount-G
(Southern Biotechnology Associates, Birmingham, AL). Unless
otherwise stated, images shown are single Z-section images for co-
localization assessment. All experiments were repeated at least
three times and representative results are shown.
Electron Microscopy
EM analysis was carried out at the EM Facility of Centro de
Biologı´a Molecular Severo Ochoa (CSIC, Madrid). For conven-
tional EM analysis cell monolayers were fixed in situ with 2%
glutaraldehyde in So¨rensen phosphate Na/K buffer (pH 7.4).
Fixed cells were processed for embedding in Epoxy, TAAB 812
Resin (TAAB Laboratories, Berkshire, England). Subsequently,
cells were subjected to postfixation with 1% osmium tetroxide/
0.8% potassium ferrocyanide, incubation with 0.15% tanic acid,
incubation with 2% uranyl acetate and dehydration in increasing
concentrations of ethanol. Infiltration of the resin was accom-
plished by increasing concentrations of Epon/ethanol. After
polymerization of infiltrated samples, ultrathin sections were
stained with saturated uranyl acetate and lead citrate and
examined at 80 kV in a Jeol JEM-1010 (Tokyo, Japan) electron
microscope. For immuno-electron microscopy cells were processed
by freeze substitution. Cells were fixed in situ with 4%
paraformaldehyde/0.1% glutaraldehyde in 0.1 M phosphate
buffer (pH 7.2). Cells were embedded in 10% gelatine, cryopro-
tected with 30% glycerol and frozen in liquid nitrogen. Freeze
substitution was carried out at 285uC in methanol containing
0.5% uranyl acetate in an Automatic Freeze-Substitution system
(AFS, Leica). Samples were later infiltrated with Lowicryl HM20
and polymerized by UV irradiation at 245uC for two days. Ultra
thin Lowicryl sections were obtained in a Reichert-Jung Ultracut
E ultramicrotome. Samples were examined as above. For
immunogold labelling the ultra thin sections were placed
sequentially on top of drops of the different solutions: TBS
(30 mM Tris-HCl, pH 8.0, 150 mM NaCl), 0.2 M ammonium
chloride in PBS, blocking buffer (TBS +0.1% BSA and 1%
gelatine) and rabbit anti-GFP antibody (Invitrogen) diluted 1:100
in blocking buffer. After washing, grids were incubated with
protein A-15 nm gold conjugate (Cell Microscopy Center.
University Medical Center. Utrecht, The Netherlands). After
washing, grids were air dried and counterstained with 2% aqueous
uranyl acetate and 1% lead citrate. Grids were examined as above.
Estimation of Protein Stability
Protein half-life was evaluated by time-course experiments in
the presence of CHX and Western blot analysis. Stability of the
various constructs used was assessed by cell transfection followed
by tripsinization to split cells in identical aliquots. After attachment
to substrate, cells were treated with CHX and construct levels were
estimated by Western blot.
Quantification and Statistics
The degree of colocalization of the different constructs was
analyzed with software from Leica and Scion Corporation for
image analysis. Results are presented as average values 6 SD or
SEM, as indicated. Average values were compared by Student’s t-
test for unpaired observations.
Supporting Information
Figure S1 Co-localization of RhoB and lysosomal proteases. (a)
The distribution of RhoB (red) and cathepsin B (CB, green) in
BAEC treated with vehicle or 10 mM chloroquine for 24 h was
assessed by IF, nuclei were stained with DAPI (blue); bar, 20 mm.
Graphs represent the fluorescence intensity profile along the lines
depicted in the images, showing the points of co-localization.
Results are representative of three assays. (b) The percentage of
cells showing five or more points of co-localization of RhoB and
cathepsin B was calculated by monitoring 40 cells per experimen-
tal condition from three different experiments and it is shown as
average values 6 standard error of mean (SEM).
Found at: doi:10.1371/journal.pone.0008117.s001 (6.04 MB TIF)
Figure S2 Effect of autophagy modulation on RhoB levels and
degradation. (a) MEFs from wt and Atg5(2/2) mice were
incubated with CHX to block new protein synthesis and the
levels of endogenous RhoB were assessed at the indicated times by
Western blot. (b) BAEC were treated in the absence or presence of
10 mM 3-methyladenine (3-MA) for 24 h and RhoB levels were
estimated as above. Dotted lines show sites where lanes from the
same gel have been cropped. Results are average values6 SEM of
three experiments. (c) BAEC were pretreated with 3-MA for
30 min, after which, CHX was added and levels of RhoB were
analyzed at the indicated times. Results are average values6 SEM
of three experiments.
Found at: doi:10.1371/journal.pone.0008117.s002 (2.29 MB TIF)
Figure S3 Effect of lysosomal inhibitors on the size and pattern
of RhoB-positive vesicles. (a) BAEC were transfected with GFP-
RhoB as in Fig. 2c and the size distribution of RhoB-positive
vesicles was determined by measuring 60 randomly taken RhoB-
positive vesicles per experimental condition from three experi-
ments. The proportion of vesicles of the indicated sizes is expressed
as percentage of the total. (b) Multivesicular pattern of chloro-
quine-elicited GFP-RhoB and Lamp1-GFP vesicles in BAEC
transfected as in Fig. 2c. Bars, 5 mm.
Found at: doi:10.1371/journal.pone.0008117.s003 (1.92 MB TIF)
Figure S4 Effect of U18666A on RhoB stability. BAEC were
treated with 10 mM U18666A for 24 h. Levels of endogenous
RhoB and of RhoGDI (as control) were assessed by Western blot
at the indicated times after CHX addition. Results shown are
average values 6 SEM of four experiments.
Found at: doi:10.1371/journal.pone.0008117.s004 (1.76 MB TIF)
Figure S5 Co-localization of GFP-RhoB with cholesterol in
control or NPC fibroblasts. Control or NPC fibroblasts were
transfected with GFP-RhoB. Co-localization with cholesterol was
evaluated in fixed cells stained with filipin. Bars, 20 mm. Co-
localization is shown as average values 6 SEM of determinations
from three experiments (*p,0.05 vs control).
Found at: doi:10.1371/journal.pone.0008117.s005 (3.21 MB TIF)
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Figure S6 Levels of RhoGDI in BAEC detected by IF before
and after CHX treatment. BAEC were treated as in Fig. 4, and
fixed. Endogenous RhoGDI (in red) was detected by IF. Nuclei
were stained with DAPI. Images shown are overall projections.
Bars, 20 mm.
Found at: doi:10.1371/journal.pone.0008117.s006 (4.04 MB TIF)
Figure S7 Effect of inhibitors of isoprenylation and palmitoyla-
tion on the levels of endogenous RhoB protein or of RhoB
constructs in different cell types. (a) NIH-3T3 fibroblasts were
transiently transfected with GFP or with GFP-RhoB, and construct
levels were assessed by Western blot with an anti-GFP antibody
after 24 h treatment with simvastatin (Sv) or 2-bromopalmitate (2-
BP). (b) NIH-3T3 fibroblasts or BAEC were treated as in (a) and the
levels of the indicated proteins were assessed by Western blot.
Dotted lines show sites where lanes from the same gel have been
cropped. (c) BAEC were transiently transfected with GFP-RhoB,
treated with simvastatin or 2-BP for 3 h and visualized by live
confocal microscopy. Note that in simvastatin-treated cells, GFP-
RhoB can be detected in the nucleus, which is indicative of the
presence of non isoprenylated construct. In contrast, in 2-BP-
treated cells the appearance of GFP-RhoB is more diffuse than in
control cells but the nucleus is excluded, as expected from an
isoprenylated construct. Bars, 20 mm.
Found at: doi:10.1371/journal.pone.0008117.s007 (3.78 MB TIF)
Figure S8 Cellular distribution and stability of GFP-RhoGDI
and GFP-RhoGDI-8. (a) BAEC were transiently transfected with
the indicated constructs as in Figure 6, treated with 10 mM
chloroquine for 24 h and incubated with 25 nM LTR for 15 min
before observation of live cells by confocal microscopy. Bar,
20 mm. (b,c) NIH-3T3 fibroblasts were stably transfected with the
indicated constructs. Protein stability (b) and subcellular localiza-
tion of constructs in control and chloroquine-treated cells (c) were
assessed as described in Fig. 6, after 30 days in culture. Bar,
20 mm.
Found at: doi:10.1371/journal.pone.0008117.s008 (6.51 MB TIF)
Figure S9 Hypothetical model for the degradation pathway of
RhoB and -CINCCKVL chimeric proteins. Isoprenylated and
palmitoylated RhoB is targeted to intracellular vesicles, mainly
Rab7-, Lamp1-positive late endosomes, and to the plasma
membrane. The association of the ESCRT complexes on the
membrane of late endosomes promotes the invagination of the
membrane. The ATPase Vps4 promotes the dissociation of the
ESCRT proteins which is required for the intraluminal release of
the invaginated vesicles. The late endosome-specific lipid LBPA
promotes luminal vesicle formation due to its cone-shaped
structure and controls endosome cholesterol content. Our results
support a hypothesis according to which late-endosome associated
RhoB may be delivered to intraluminal vesicles of MVB in a Vps4-
and LBPA-dependent fashion, for degradation in acidic compart-
ments. Inhibition of vesicular acidification with chloroquine or of
lysosomal proteases with protease inhibitors results in the
formation of dilated MVB in which RhoB accumulates. Genetic
or pharmacological disruption of late endosome specific lipid
dynamics also alters RhoB sorting. The proposed points of
regulation of RhoB targeting to the endo-lysosomal pathway are
shown in blue boxes. Based on our experimental observations, -
CINCCKVL chimeric proteins would follow a similar pathway for
rapid protein degradation. Ub, ubiquitin; GFR, growth factor
receptor; GF, growth factor.
Found at: doi:10.1371/journal.pone.0008117.s009 (4.56 MB TIF)
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